Skip to content
Screener

Atrium Therapeutics RNA Q1 2026 earnings

Reported May 14, 2026 · Before market open

Revenue$19.6MBeat by $17.6M
EPS-$0.97Beat by $0.08
Revenue estimate$2.0M
EPS estimate-$1.05

Next report

Nov 12, 2026 (in 2 months)
Revenue estimate$15.0M
EPS estimate-$0.87

Versus estimates

Revenue

Q2 2026$3.0MBeat by $2.3M
Q1 2026$19.6MBeat by $17.6M
Q4 2025$859.0KMiss by $1.3M

Diluted EPS

Q2 2026-$1.18Beat by $0.24
Q1 2026-$0.97Beat by $0.08
Q4 2025-$1.70Miss by $0.46

FAQ

When did Atrium Therapeutics report Q1 2026 earnings?
Atrium Therapeutics (RNA) reported Q1 2026 earnings on May 14, 2026 before market open.
What were Atrium Therapeutics's Q1 2026 revenue and EPS?
Atrium Therapeutics reported revenue of $19.6M and eps of $-0.97 for Q1 2026.
Did Atrium Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $2.0M by $17.6M. EPS beat the consensus estimate of $-1.05 by $0.08.
Where can I find Atrium Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-224238) and the 10-Q periodic report (0001193125-26-224243) directly on SEC EDGAR. The filing index links above go to sec.gov.